{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:15Z","timestamp":1774566495013,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.pupt.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T10:09:28Z","timestamp":1445767768000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A comparison of the efficacy of once-daily fluticasone furoate\/vilanterole with twice-daily fluticasone propionate\/salmeterol in asthma-COPD overlap syndrome"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-3308","authenticated-orcid":false,"given":"Yoshihisa","family":"Ishiura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johsuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2015.10.005_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/thx.2008.108027","article-title":"The overlap syndrome of asthma and COPD: what are its features and how important is it?","volume":"64","author":"Gibson","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2015.10.005_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000352053","article-title":"Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome","volume":"87","author":"Fu","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2015.10.005_bib0020","series-title":"Diangnosis of Chronic Airflow Limitation: Astma, COPD and Asthma-COPD Overlap Syndrome (ACOS)","author":"Global initiative for asthma (GINA)","year":"2014"},{"key":"10.1016\/j.pupt.2015.10.005_bib0025","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199810223391703","article-title":"15-year follow-up study of ventilatory function in adults with asthma","volume":"339","author":"Lange","year":"1998","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1465-9921-12-127","article-title":"COPD gene investigators. The clinical features of the overlap between COPD and asthma","volume":"12","author":"Hardin","year":"2011","journal-title":"Respir. Res"},{"key":"10.1016\/j.pupt.2015.10.005_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.07-2317","article-title":"Burden of concomitant asthma and COPD in a medicaid population","volume":"134","author":"Shaya","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0040","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1378\/chest.128.4.2099","article-title":"Patterns of comorbidities in newly diagnosed COPD and asthma in primary care","volume":"128","author":"Soriano","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0045","first-page":"861926","article-title":"The asthma-COPD overlap syndrome: a common clinical problem in the elderly","volume":"2011","author":"Zeki","year":"2011","journal-title":"J.\u00a0Allergy (Cairo)"},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2015.10.005_bib0050","first-page":"1","article-title":"Spanish guideline for COPD (GesEPOC). Update 2014","author":"Miravitlles","year":"2014","journal-title":"Arch. Bronconeumol"},{"key":"10.1016\/j.pupt.2015.10.005_bib0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejphar.2011.08.022","article-title":"Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells","volume":"670","author":"Rossios","year":"2011","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.pupt.2015.10.005_bib0060","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.112.198481","article-title":"In\u00a0vitro pharmacological characterization of vilanterol, a novel long-acting \u03b22-adrenoceptor agonist with 24-hour duration of action","volume":"344","author":"Slack","year":"2011","journal-title":"Pharmacol. Exp. Ther"},{"key":"10.1016\/j.pupt.2015.10.005_bib0065","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1378\/chest.13-0178","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol compared with fluticasone propionate\/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial","volume":"144","author":"Woodcock","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1183\/09031936.00054213","article-title":"A\u00a0comparison of the efficacy and safety of once-daily fluticasone furoate\/vilanterol with twice-daily fluticasone propionate\/salmeterol in moderate to very severe COPD","volume":"43","author":"Agust\u00ed","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.10.005_bib0075","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.rmed.2014.05.008","article-title":"Efficacy and safety of once-daily fluticasone furoate\/vilanterol (100\/25 mcg) versus twice-daily fluticasone propionate\/salmeterol (250\/50 mcg) in COPD patients","volume":"108","author":"Dransfield","year":"2014","journal-title":"Respir. Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4168\/aair.2014.6.4.316","article-title":"Systemic inflammation in older adults with asthma-COPD overlap syndrome","volume":"6","author":"Fu","year":"2014","journal-title":"Allergy Asthma Immunol. Res"},{"key":"10.1016\/j.pupt.2015.10.005_bib0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/thx.2007.089193","article-title":"Proportional classification of COPD phenotypes","volume":"63","author":"Marsh","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2015.10.005_bib0090","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1378\/chest.124.2.474","article-title":"The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom","volume":"124","author":"Soriano","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0095","first-page":"370","article-title":"COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma","volume":"19","author":"Ishiura","year":"2009","journal-title":"J.\u00a0Investig. Allergol. Clin. Immunol"},{"key":"10.1016\/j.pupt.2015.10.005_bib0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1745-9974-6-7","article-title":"Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome","volume":"6","author":"Ishiura","year":"2010","journal-title":"Cough"},{"key":"10.1016\/j.pupt.2015.10.005_bib0105","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1183\/09031936.03.00089403","article-title":"ERS task force on respiratory impedance measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments","volume":"22","author":"Oostveen","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.10.005_bib0110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/15412555.2011.626818","article-title":"Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma","volume":"8","author":"Mori","year":"2011","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2015.10.005_bib0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1465-9921-7-67","article-title":"Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children","volume":"7","author":"Alving","year":"2006","journal-title":"Respir. Res"},{"key":"10.1016\/j.pupt.2015.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1164\/rccm.201110-1843OC","article-title":"Usefulness of the chronic obstructive pumonary disease assessment test to evaluate severity of COPD exacerbations","volume":"185","author":"Mackay","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000336549","article-title":"Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients","volume":"84","author":"Kelly","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2015.10.005_bib0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: A survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J.\u00a0Allergy Clin. Immunol"},{"key":"10.1016\/j.pupt.2015.10.005_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2152\/jmi.60.61","article-title":"Asthma exacerbations after the East Japan disaster","volume":"60","author":"Ishiura","year":"2013","journal-title":"J.\u00a0Med. Invest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1183\/09031936.06.00025805","article-title":"Chronic obstructive pulmonary disease: current burden and future projections","volume":"27","author":"Lopez","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.10.005_bib0145","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"GOLD scientific committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0150","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projection of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0155","series-title":"Chronic Obstructive Pulmonary Disease Phenotypes (COPD). Burden of COPD","author":"WHO","year":"2012"},{"key":"10.1016\/j.pupt.2015.10.005_bib0160","first-page":"1","article-title":"Deaths: final data for 2008","volume":"59","author":"Mini\u00f1o","year":"2011","journal-title":"Natl. Vital Stat. Rep"},{"key":"10.1016\/j.pupt.2015.10.005_bib0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.200912-1843CC","article-title":"Chronic obstructive pulmonary disease phenotypes: the future of COPD","volume":"182","author":"Han","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40266-012-0042-z","article-title":"Managing older peoples with coexistent asthma and chronic obstructive lung disease; diagnostic and therapeutic challenge","volume":"30","author":"McDonald","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pupt.2015.10.005_bib0175","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1183\/09031936.00129607","article-title":"Bronchodilator responsiveness in patients with COPD","volume":"31","author":"Tashkin","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.10.005_bib0180","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/15412555.2011.611200","article-title":"Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population","volume":"8","author":"Diaz-Guzman","year":"2011","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2015.10.005_bib0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/02770903.2011.555576","article-title":"Overlap syndrome of asthma and COPD predicts low quality of life","volume":"48","author":"Kauppi","year":"2011","journal-title":"J.\u00a0Asthma"},{"key":"10.1016\/j.pupt.2015.10.005_bib0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000109374","article-title":"Dry powder inhalers: which factors determine the frequency of handling erraors?","volume":"75","author":"Wieshammer","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2015.10.005_bib0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/089426803769017613","article-title":"Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care","volume":"16","author":"Molimard","year":"2003","journal-title":"J.\u00a0Aerosl. Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0200","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.rmed.2011.01.005","article-title":"Gruppo educazionale associazione Italiana pneumologi ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control","volume":"105","author":"Melani","year":"2011","journal-title":"Respir. Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2466-13-72","article-title":"Qualitative assessment of attributes and ease of use of the ELLIPTA\u2122 dry powder inhaler for delivery of maintenance therapy for asthma and COPD","volume":"13","author":"Svedsater","year":"2013","journal-title":"BMC Pulm. Med"},{"key":"10.1016\/j.pupt.2015.10.005_bib0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1152\/ajplung.00108.2007","article-title":"Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in\u00a0vitro and in an in\u00a0vivo model of respiratory inflammatory disease","volume":"293","author":"Salter","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol"},{"key":"10.1016\/j.pupt.2015.10.005_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1378\/chest.11-2231","article-title":"The efficacy and safety of the novel long-acting \u03b22 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial","volume":"142","author":"Hanania","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.10.005_bib0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1183\/09031936.00121411","article-title":"24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids","volume":"40","author":"L\u00f6tvall","year":"2012","journal-title":"Eur. Respir. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915300055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915300055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T05:25:24Z","timestamp":1537248324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553915300055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":43,"alternative-id":["S1094553915300055"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2015.10.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of the efficacy of once-daily fluticasone furoate\/vilanterole with twice-daily fluticasone propionate\/salmeterol in asthma-COPD overlap syndrome","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}